0001479290-24-000090.txt : 20240503
0001479290-24-000090.hdr.sgml : 20240503
20240503084758
ACCESSION NUMBER: 0001479290-24-000090
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240501
FILED AS OF DATE: 20240503
DATE AS OF CHANGE: 20240503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ware Olivia C
CENTRAL INDEX KEY: 0001663771
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 24910953
MAIL ADDRESS:
STREET 1: 11726 SAN VICENTE BLVD
STREET 2: SUITE 650
CITY: LOS ANGELES
STATE: CA
ZIP: 90049
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
BUSINESS PHONE: 6157247755
MAIL ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
wk-form4_1714740469.xml
FORM 4
X0508
4
2024-05-01
0
0001479290
Revance Therapeutics, Inc.
RVNC
0001663771
Ware Olivia C
C/O REVANCE THERAPEUTICS, INC
1222 DEMONBREUN STREET, 20TH FLOOR
NASHVILLE
TN
37203
1
0
0
0
0
Common Stock
2024-05-01
4
A
0
15000
0
A
31675
D
Stock Option (Right to buy)
3.795
2024-05-01
4
A
0
23458
0
A
2034-04-30
Common Stock
23458
23458
D
Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy.
/s/ Dwight Moxie, Attorney-in-Fact
2024-05-03